Skip to main content
    T

    Tango Therapeutics Inc (TNGX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $24.17
    -1.33 (-5.22%)

    Market Cap: $4.32B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Tango Therapeutics Inc (TNGX) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Tango Therapeutics (TNGX) to earn -$1.46 per share in the fiscal year ending Dec 31, 2026. Of 13 analysts, 12 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 3 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 13 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 92% of the ratings.

    RatingAnalystsShare
    Strong Buy17.7%
    Buy1184.6%
    Hold17.7%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    13

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss.

    Fiscal year ending Dec 31, 2026
    -$1.46
    EPS consensus
    Fiscal year ending Dec 31, 2027
    -$1.80
    EPS consensus, revenue $3.14M
    Next report
    Mar 3, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$1.46-$1.63 to -$1.1413N/AN/A12
    Dec 31, 2027-$1.80-$2.36 to -$1.2412$3.14MN/A10

    Quarterly Estimates

    The EPS consensus falls from -$0.41 for the quarter ending Dec 31, 2026 to -$0.43 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.41-$0.47 to -$0.3315N/AN/A14
    Mar 31, 2027-$0.43-$0.50 to -$0.344$1.58MN/A5

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 0 upward and 5 downward EPS revisions. Cuts outnumber raises in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202603
    Fiscal year ending Dec 31, 202701
    Quarter ending Mar 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.38.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$1.46-$1.40-$1.40-$1.40-$1.38N/A
    Fiscal year ending Dec 31, 2027-$1.80-$1.67-$1.69-$1.69-$1.64N/A
    Quarter ending Mar 31, 2027-$0.43-$0.38-$0.37-$0.37-$0.36N/A

    Frequently Asked Questions About TNGX

    What is the TNGX stock forecast?

    Consensus analyst estimates put Tango Therapeutics's EPS at -$1.46 for the fiscal year ending Dec 31, 2026. The consensus rating from 13 analysts is Buy.

    How do analysts rate TNGX stock?

    Of 13 analysts covering Tango Therapeutics, 1 rates it Strong Buy, 11 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from TNGX next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.46, with estimates from -$1.63 to -$1.14 from 13 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.80, with estimates from -$2.36 to -$1.24 from 12 analysts.

    What revenue do analysts expect from Tango Therapeutics next year?

    For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $3.14M.

    How many analysts cover TNGX?

    13 analysts rate Tango Therapeutics stock, and 13 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.